Antibody-drug conjugates in urinary tumors: clinical application, challenge, and perspectives
Keqiang Li1,2, Guoqing Xie1,2, Xiyue Deng1,2
1Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Abstract:
Urinary tumors primarily consist of kidney, urothelial, and prostate malignancies, which pose significant treatment challenges, particularly in advanced stages. Antibody-drug conjugates (ADCs) have emerged as a promising therapeutic approach, combining monoclonal antibody specificity with cytotoxic chemotherapeutic payloads. This review highlights recent advancements, opportunities, and challenges in ADC application for urinary tumors. We discuss the FDA-approved ADCs and other novel ADCs under investigation, emphasizing their potential to improve patient outcomes. Furthermore, we explore strategies to address challenges, such as toxicity management, predictive biomarker identification, and resistance mechanisms. Additionally, we examine the integration of ADCs with other treatment modalities, including immune checkpoint inhibitors, targeted therapies, and radiation therapy. By addressing these challenges and exploring innovative approaches, the development of ADCs may significantly enhance therapeutic options and outcomes for patients with advanced urinary tumor.
Insights
Antibody-drug conjugates (ADCs) show promise for treating advanced urinary tumors like kidney and prostate cancer. Research focuses on overcoming challenges to improve patient outcomes with these targeted therapies.
Area of Science:
- Oncology
- Pharmacology
Background:
- Urinary tumors, including kidney, urothelial, and prostate cancers, present significant treatment challenges, especially in advanced stages.
- Antibody-drug conjugates (ADCs) offer a novel therapeutic strategy by combining targeted antibody delivery with potent cytotoxic payloads.
Purpose of the Study:
- To review recent advancements, opportunities, and challenges in applying ADCs for urinary tumors.
- To discuss current FDA-approved and investigational ADCs and their potential impact on patient outcomes.
Main Methods:
- Literature review of recent advancements in ADC therapy for urinary malignancies.
- Analysis of FDA-approved and emerging ADCs, including strategies for toxicity management and biomarker identification.
- Exploration of ADC combination therapies with immunotherapy, targeted agents, and radiation.
Main Results:
- ADCs represent a promising therapeutic avenue for advanced urinary tumors, with several agents approved and under investigation.
- Key challenges include managing toxicity, identifying predictive biomarkers, and overcoming resistance mechanisms.
- Integration with other treatment modalities may further enhance efficacy.
Conclusions:
- ADCs hold significant potential to improve treatment options and outcomes for patients with advanced urinary tumors.
- Addressing challenges and exploring innovative combinations are crucial for maximizing ADC therapeutic benefits.
